DongKoo Bio & Pharma Co., Ltd. (KOSDAQ:006620)

South Korea flag South Korea · Delayed Price · Currency is KRW
5,580.00
+90.00 (1.64%)
At close: Oct 2, 2025
1.64%
Market Cap150.62B
Revenue (ttm)242.55B
Net Income (ttm)5.96B
Shares Out27.04M
EPS (ttm)218.51
PE Ratio25.49
Forward PEn/a
Dividend120.00 (2.15%)
Ex-Dividend DateDec 27, 2024
Volume469,982
Average Volume1,378,996
Open5,530.00
Previous Close5,490.00
Day's Range5,500.00 - 5,630.00
52-Week Range4,300.00 - 6,720.00
Beta0.63
RSI62.60
Earnings DateNov 14, 2025

About DongKoo Bio & Pharma

DongKoo Bio & Pharma Co., Ltd. manufactures and sells pharmaceuticals in South Korea. The company provides prescription drugs, such as antihistamines, dermatological oral medications, ophthalmic solutions, skeletal muscle relaxants, anti-inflammatory enzymes, antivirals, antibacterial agents, and for the treatment of allergies, liver diseases, mental illnesses, obesity, brain nervous, and endocrine systems; over-the-counter medicines, such as dermatological external preparations, antifungal agents, active probiotic intestinal supplements, antip... [Read more]

Industry Pharmaceutical Preparations
Founded 1970
Employees 404
Stock Exchange KOSDAQ
Ticker Symbol 006620
Full Company Profile

Financial Performance

In 2024, DongKoo Bio & Pharma's revenue was 249.27 billion, an increase of 15.57% compared to the previous year's 215.69 billion. Earnings were 2.04 billion, a decrease of -82.77%.

Financial Statements

News

There is no news available yet.